Protalix BioTherapeutics, Inc.
ASE: PLXLive Quote
About Protalix BioTherapeutics, Inc.
Healthcare
Biotechnology
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
📊 Fundamental Analysis
Protalix BioTherapeutics, Inc. demonstrates a profit margin of -12.5%, which is below the sector average, suggesting competitive pressure.
The company recently reported -49.9% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -14.4%, which indicates that capital utilization is currently under pressure.
At a current price of $2.30, PLX currently sits at the 52nd percentile of its 52-week range (Range: $1.32 - $3.19).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$157.92M
Trailing P/E
--
Forward P/E
3.71
Beta (5Y)
-0.09
52W High
$3.19
52W Low
$1.32
Avg Volume
1.25M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App